Equity Profile

KNSA

Kiniksa Pharmaceuticals International, plc

Health CareBiotechnology$3.8B

Jul28Tue

Pre-Earnings Brief

UpcomingQ2-2026Pre-Market9:00 AM EDT

Company Snapshot

Kiniksa Pharmaceuticals International, plc (KNSA) is a biotechnology company focused on developing and commercializing innovative therapies for patients with serious diseases. Operating in the healthcare sector, Kiniksa's work is crucial as it aims to address unmet medical needs, particularly in immunology and rare diseases.

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

N/A

Revenue Growth

Revenue growth reflects the company's ability to expand its market presence and is essential for assessing its overall performance.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

KNSA Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

50%

Avg EPS Surprise

-110.97%

Avg Stock Reaction

+6.62%

Last Quarter Recap

In Q1-2026, Kiniksa reported an EPS of $0.27, significantly beating expectations of $0.18, which led to a stock increase of 23.48% the following day. However, revenue figures were not disclosed, leaving some uncertainty about overall performance.

Management Promises & Guidance

Expectations

Wall Street Expectations

Overall, expectations are mixed as Kiniksa has shown volatility in its earnings history, with a 50% EPS beat rate. Investors are keen to see if the company can maintain its positive momentum from the last quarter.

Bull Case

If Kiniksa continues to exceed EPS expectations and shows strong revenue growth, it could reinforce investor confidence and drive the stock higher.

Bear Case

Conversely, if the company fails to meet earnings expectations or provides weak guidance, it could lead to a significant drop in stock price, reflecting investor disappointment.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will be the EPS for Q2-2026?

Given the company's recent performance, a strong EPS could indicate continued growth and investor confidence, while a miss could lead to a sharp decline.

What is the outlook for revenue growth in the upcoming quarters?

Revenue growth is critical for assessing the company's ability to sustain its operations and invest in future projects, impacting long-term investor sentiment.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate Kiniksa's potential for continued earnings growth, as recent performance suggests a stronger trajectory than anticipated.

Supporting Evidence

Kiniksa's recent EPS surprise of +50% indicates a trend of outperforming expectations.

The options market is pricing in a significant move, suggesting that traders expect volatility that could favor a positive outcome.

Key Risk

If Kiniksa's EPS comes in above $0.30, it could significantly shift market sentiment towards a more bullish outlook.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's focus is on whether Kiniksa can sustain its recent earnings momentum and provide positive guidance for future growth.

Bull Confirmed If

An EPS of $0.30 or higher would confirm the bull case, indicating strong profitability.

Bear Confirmed If

An EPS below $0.18 would confirm the bear case, suggesting potential struggles in maintaining profitability.

Pre-Earnings Positioning

Options Market

Implied Move

±24.6%

Historical Avg

±13.3%

Pricing rich

The options market is pricing in a significant move of about 24.6%, indicating heightened uncertainty or anticipation around the earnings report.

Options are pricing ±24.6% while KNSA has averaged ±13.3% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.5%

30d HV

73.2%

Calls (4K)P/C Ratio: 1.10Puts (800)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

This setup has occurred 30 times across Health Care in the last 2 years. 13 of 29 faded and 16 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 5.5%, with a raw directional average of +2.9% (modestly positive historical bias).

Edge

Insider Activity

Open-market trades by officers, directors, and 10%+ holders over the trailing 90 days.

Bought

$0.00

0 sh

0 insiders

Sold

$388,834.32

8,328 sh

2 insiders

Net

$388,834.32

Net selling

Most Active Insiders· 2 open-market trades

CHIEF ACCOUNTING OFFICERMegna Michael R
$309,321.25

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Kiniksa beats expectations, history suggests the stock could rise by around 19.81%, confirming the positive growth narrative.

In-Line / Cautious

If results are in line with expectations, the stock may experience a muted reaction as investors await further guidance.

Miss

Should the company miss earnings expectations, history indicates a potential decline of about 6.58%, reflecting investor disappointment.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new product launches or pipeline developments.
2Management's commentary on market conditions and competitive landscape.
3Insights into customer adoption rates for existing products.
4Guidance on revenue expectations for the next quarter.
5Details on any operational challenges faced during the quarter.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Jul27

DYNBMO

Dyne Therapeutics, Inc.

Insider activity

PreviewView

Jul

Company Snapshot

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

N/A

Revenue Growth

Revenue growth reflects the company's ability to expand its market presence and is essential for assessing its overall performance.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

KNSA Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

50%

Avg EPS Surprise

-110.97%

Avg Stock Reaction

+6.62%

Last Quarter Recap

Management Promises & Guidance

Expectations

Wall Street Expectations

Bull Case

If Kiniksa continues to exceed EPS expectations and shows strong revenue growth, it could reinforce investor confidence and drive the stock higher.

Bear Case

Conversely, if the company fails to meet earnings expectations or provides weak guidance, it could lead to a significant drop in stock price, reflecting investor disappointment.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will be the EPS for Q2-2026?

Given the company's recent performance, a strong EPS could indicate continued growth and investor confidence, while a miss could lead to a sharp decline.

What is the outlook for revenue growth in the upcoming quarters?

Revenue growth is critical for assessing the company's ability to sustain its operations and invest in future projects, impacting long-term investor sentiment.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate Kiniksa's potential for continued earnings growth, as recent performance suggests a stronger trajectory than anticipated.

Supporting Evidence

Kiniksa's recent EPS surprise of +50% indicates a trend of outperforming expectations.

The options market is pricing in a significant move, suggesting that traders expect volatility that could favor a positive outcome.

Key Risk

If Kiniksa's EPS comes in above $0.30, it could significantly shift market sentiment towards a more bullish outlook.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's focus is on whether Kiniksa can sustain its recent earnings momentum and provide positive guidance for future growth.

Bull Confirmed If

An EPS of $0.30 or higher would confirm the bull case, indicating strong profitability.

Bear Confirmed If

An EPS below $0.18 would confirm the bear case, suggesting potential struggles in maintaining profitability.

Pre-Earnings Positioning

Options Market

Implied Move

±24.6%

Historical Avg

±13.3%

Pricing rich

The options market is pricing in a significant move of about 24.6%, indicating heightened uncertainty or anticipation around the earnings report.

Options are pricing ±24.6% while KNSA has averaged ±13.3% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.5%

30d HV

73.2%

Calls (4K)P/C Ratio: 1.10Puts (800)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

Edge

Insider Activity

Open-market trades by officers, directors, and 10%+ holders over the trailing 90 days.

Bought

$0.00

0 sh

0 insiders

Sold

$388,834.32

8,328 sh

2 insiders

Net

$388,834.32

Net selling

Most Active Insiders· 2 open-market trades

CHIEF ACCOUNTING OFFICERMegna Michael R
$309,321.25

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Kiniksa beats expectations, history suggests the stock could rise by around 19.81%, confirming the positive growth narrative.

In-Line / Cautious

If results are in line with expectations, the stock may experience a muted reaction as investors await further guidance.

Miss

Should the company miss earnings expectations, history indicates a potential decline of about 6.58%, reflecting investor disappointment.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new product launches or pipeline developments.
2Management's commentary on market conditions and competitive landscape.
3Insights into customer adoption rates for existing products.
4Guidance on revenue expectations for the next quarter.
5Details on any operational challenges faced during the quarter.